248 - References

References

252 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 References

1. Vermeulen JM, et al. Clozapine and long-­term mortality risk in patients with schizophrenia: a systematic review and meta-­analysis of studies lasting 1.1–12.5 years. Schizophr Bull 2019; 45:315–329.
2. Walker AM, et al. Mortality in current and former users of clozapine. Epidemiology 1997; 8:671–677.
3. van der Zalm Y, et al. Clozapine and mortality: a comparison with other antipsychotics in a nationwide Danish cohort study. Acta Psychiatr Scand 2021; 143:216–226.
4. Munro J, et al. Active monitoring of 12760 clozapine recipients in the UK and Ireland. Br J Psychiatry 1999; 175:576–580.
5. Correll CU, et al. Mortality in people with schizophrenia: a systematic review and meta-­analysis of relative risk and aggravating or attenuating factors. World Psychiatry 2022; 21:248–271.
6. Solmi M, et al. Antipsychotics use is associated with greater adherence to cardiometabolic medications in patients with schizophrenia: results from a nationwide, within-­subject design study. Schizophr Bull 2022; 48:166–175.
7. Li XH, et al. The prevalence of agranulocytosis and related death in clozapine-­treated patients: a comprehensive meta-­analysis of observational studies. Psychol Med 2020; 50:583–594.
8. Myles N, et al. Meta-­analysis examining the epidemiology of clozapine-­associated neutropenia. Acta Psychiatr Scand 2018; 138:101–109.
9. Prokopez CR, et al. Clozapine rechallenge after neutropenia or leucopenia. J Clin Psychopharmacol 2016; 36:377–380.
10. Manu P, et al. Clozapine rechallenge after major adverse effects: clinical guidelines based on 259 cases. Am J Ther 2018; 25:e218–e223.
11. Oloyede E, et al. There is life after the UK Clozapine Central Non-­Rechallenge Database. Schizophr Bull 2021; 47:1088–1098.
12. Taylor D, et  al. Distinctive pattern of neutrophil count change in clozapine-­associated, life-­threatening agranulocytosis. Schizophrenia (Heidelb) 2022; 8:21.
13. Taylor D, et al. Severe neutropenia unrelated to clozapine in patients receiving clozapine. J Psychopharmacol 2024; 38:624–635.
14. Oloyede E, et al. Identifying clinically relevant agranulocytosis in people registered on the UK clozapine Central Non-­Rechallenge Database: retrospective cohort study. Br J Psychiatry 2024; 225:484–491.
15. Oloyede E, et al. Benign ethnic neutropenia: an analysis of prevalence, timing and identification accuracy in two large inner-­city NHS hospitals. BMC Psychiatry 2021; 21:502.